News
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this January. The price action doesn't jive with the biopharmaceutical company's cash flows and the
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this January. The price action doesn't jive with the biopharmaceutical company's cash flows and the
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this January. The price action doesn't jive with the biopharmaceutical company's cash flows and the
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q1 2024 Earnings CallMay 07, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q1 2024 Earnings CallMay 06, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q1 2024 Earnings CallMay 06, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q1 2024 Earnings CallMay 06, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q1 2024 Earnings CallMay 06, 2024, 8:00 a.m. ET
Operator
Source Fool.com
3 Reasons to Buy AbbVie Stock on the Dip
It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as
3 No-Brainer Stocks to Buy in May
Don't believe the adage to "sell in May and go away." Buying stocks can still be a smart move, especially if you're a long-term investor.
Three Motley Fool contributors have identified stocks they
3 No-Brainer Stocks to Buy in May
Don't believe the adage to "sell in May and go away." Buying stocks can still be a smart move, especially if you're a long-term investor.
Three Motley Fool contributors have identified stocks they
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than
Why Amgen Stock Zoomed Nearly 12% Higher Today
Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The
Why Amgen Stock Zoomed Nearly 12% Higher Today
Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The
Why Amgen Stock Zoomed Nearly 12% Higher Today
Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The
Zoetis (ZTS) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q1 2024 Earnings CallMay 02, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Zoetis Stock Popped by Almost 6% on Thursday
Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q1 2024 Earnings CallMay 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com